ScinoPharm to build cytotoxic injectable plant in Taiwan

TAINAN, TAIWAN: ScinoPharm will invest NT$1.13 billion ($37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company’s premise at the Tainan Science Park. Design and construction of the plant is expected to begin in the second half of 2012, with completion expected in 2014. Through the expanded capabilities, ScinoPharm hopes to further solidify its leadership position in the oncological area with enhance support to its customers.

“By expanding into the field of oncological injectable formulation, ScinoPharm will be able to provide a vertically integrated, one stop shop service for our existing API customers. The global demand for oncological injectable production capacity far exceeds the supply. Many international generic customers of ours have been eagerly searching for partners who can provide a high quality and stable supply of oncological injectable drug products not to mention meet GMP requirements. We are excited to be able to fill this critical requirement,” said Dr Jo Shen, President and CEO, ScinoPharm.

© WOC News